한글목차

세계 차세대 시퀀싱 시장 규모는 2034년까지 연평균 19.9%의 성장률을 나타낼 것으로 예상됩니다.

연구 및 임상 협력 부문이 NGS 시장을 강화할 것으로 예상됩니다.

연구 및 임상 협력은 차세대 염기서열 분석(NGS) 시장 확대에 중요한 역할을 할 것으로 보입니다. 이러한 협력은 기술 혁신을 촉진하고 비용을 절감하며 NGS 기술의 용도를 확대할 수 있습니다. 임상 협력은 유전체, 생물정보학, 임상 의학, 데이터 과학 등 다양한 분야의 전문가를 모아 다학제적 혁신을 촉진하며, NGS 업계는 점점 더 많은 기업들이 주요 진단 및 제약 회사와의 제휴를 추진하고 있으며, 이는 임상 및 개인 맞춤형 의료에서 NGS의 활용을 촉진하는 중요한 단계입니다. 활용을 촉진하기 위한 중요한 발걸음을 내딛고 있습니다.

가격 압력이 시장 성장의 큰 장벽이 될 것

가격 압력은 차세대 염기서열 분석(NGS) 분야의 세계 확장에 큰 걸림돌로 작용하고 있습니다. 주요 NGS 제공업체들 간의 치열한 경쟁으로 인해 가격 경쟁이 치열해지면서 기업의 마진을 압박하고 있습니다. 신생 기업 및 대체 시퀀싱 기술(나노포어 시퀀싱 등)은 경쟁을 더욱 심화시키고 있으며, 기존 기업들은 경쟁력을 유지하기 위해 가격 인하를 강요받고 있습니다. 바이오 제약사들이 신약 발견에 대한 투자에 신중을 기하고 있어 세계 임상연구 시장은 현재 성장이 둔화되고 있습니다. 가격 압력으로 인해 제네릭 의약품의 사용이 증가하고 있으며, 이는 R&D 투자 성장을 둔화시킬 가능성이 높습니다. 처방전을 쉽게 구할 수 있게 되면서 전 세계적으로 제네릭 의약품의 사용이 빠르게 증가하고 있습니다. 이는 임상 연구 산업의 확장에 부정적인 영향을 미치고 NGS 시장에도 영향을 미칠 것으로 예상됩니다.

세계 차세대 시퀀싱(Next Generation Sequencing) 시장을 조사했으며, 시장 개요, 시장 성장에 영향을 미치는 요인 및 시장 기회 분석, 시장 규모 추이 및 예측, 각 부문별/지역별/주요 국가별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 보고서 개요

제2장 주요 요약

제3장 시장 개요

• 주요 조사 결과
• 시장 역학
• 영향 분석
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
• 공급망 분석
• 규제 프레임워크
• 신흥 시장과 메가트렌드
• Porter의 Five Forces 분석
• PESTLE 분석

제4장 차세대 시퀀싱 시장 분석 : 유형별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• 소모품
• 바이오인포매틱스
• 시퀀싱 서비스
• 프리시퀀싱 서비스
• 기기
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제5장 차세대 시퀀싱 시장 분석 : 워크플로우별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• 라이브러리 준비
• 시퀀싱
• 데이터 분석
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제6장 차세대 시퀀싱 시장 분석 : 용도별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• 종양
• 생식건강
• 유전성 질환 및 희귀질환
• 소비자 유전체학
• 애그리게노믹스 및 포렌식
• 기타
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제7장 차세대 시퀀싱 시장 분석 : 최종사용자별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• 병원 및 진료소
• 학술연구기관
• 제약 기업 및 바이오테크놀러지 기업
• 기타
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제8장 차세대 시퀀싱 시장 분석 : 지역별

• 주요 조사 결과
• 시장 규모 추이와 예측

제9장 북미의 차세대 시퀀싱 시장 분석

제10장 유럽의 차세대 시퀀싱 시장 분석

제11장 아시아태평양의 차세대 시퀀싱 시장 분석

제12장 라틴아메리카의 차세대 시퀀싱 시장 분석

제13장 중동 및 아프리카의 차세대 시퀀싱 시장 분석

제14장 기업 개요

• 경쟁 구도
• 전략적 전망
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• QIAGEN
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.
• PerkinElmer Inc.
• Eurofins Scientific
• Tecan Group
• Takara Bio
• 10x Genomics
• GenScript
• Integrated DNA Technologies
• Oxford Nanopore Technologies

제15장 결론 및 제안

• Visiongain의 결론
• 시장 진출기업에 대한 제안

영문목차

The global Next Generation Sequencing Market is projected to grow at a CAGR of 19.9% by 2034

The Next Generation Sequencing Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Research and Clinical Collaborations are Expected to Enhance the NGS Market

Research and clinical collaborations are likely to play a significant role in augmenting the next generation sequencing (NGS) market. These collaborations can drive innovation, reduce costs, and expand the application of NGS technologies. Collaborations bring together experts from various fields, such as genomics, bioinformatics, clinical medicine, and data science, fostering interdisciplinary innovation. A rising number of NGS industry players are developing partnerships with major diagnostics and pharmaceutical businesses, which is a key step towards furthering the use of NGS in clinical settings and personalised medicine. For instance, on 5th January 2024, Illumina Inc., a global pioneer in DNA sequencing and array-based technologies, said that it has entered into a collaboration with Janssen Research & Development, LLC. This will be the first cooperation to create Illumina, Inc. revolutionary molecular residual disease assay, a WGS (whole-genome sequencing) multi-cancer research service that can detect circulating tumour DNA (ctDNA) to better understand disease persistence or recurrence following clinical intervention.

Pricing Pressure has Emerged as a Significant Barrier to the Growth of the Next-Generation Sequencing Market.

Pricing pressure is a significant restraint on the global expansion of the next generation sequencing (NGS) sector. Intense rivalry among prominent NGS providers has caused price wars, which can pressure corporate margins. Emerging companies and alternative sequencing technologies (e.g., nanopore sequencing) further increase competition, forcing existing players to lower prices to remain competitive. Since biopharmaceutical companies are cautious to invest in the discovery of novel drugs, the global clinical research market is currently seeing slow growth. Price pressure is increasing the use of generic medications, which is likely to slow R&D investment growth. Due to easy access to prescriptions, the usage of generic drugs is rapidly increasing over the world. This is projected to have a negative impact on clinical research industry expansion, affecting the NGS market.

What Questions Should You Ask before Buying a Market Research Report?

• How is the next generation sequencing market evolving?
• What is driving and restraining the next generation sequencing market?
• How will each next generation sequencing submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
• How will the market shares for each next generation sequencing submarket develop from 2024 to 2034?
• What will be the main driver for the overall market from 2024 to 2034?
• Will leading next generation sequencing markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
• Who are the leading players and what are their prospects over the forecast period?
• What are the next generation sequencing projects for these leading companies?
• How will the industry evolve during the period between 2024 and 2034? What are the implications of next generation sequencing projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the next generation sequencing manufacturing market?
• Where is the next generation sequencing market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the next generation sequencing market today, and over the next 10 years:

• Our 301-page report provides 118 tables and 185 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them - NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
• Forecasts to 2034 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising vaccine contract manufacturing prices and recent developments.

Segments Covered in the Report

• Type
• Consumables
• Bioinformatics
• Sequencing Services
• Whole Exome Sequencing
• Targeted Panels
• Whole-genome Sequencing
• Others
• Pre-sequencing Services
• Library Preparation and Target Enrichment
• Quality Control
• Instruments
• Workflow
• Library Preparation
• Semi-automated
• Automated
• Sequencing
• Data Analysis
• NGS Primary Data Analysis
• NGS Secondary Data Analysis
• NGS Tertiary Data Analysis
• Application
• Oncology
• Diagnostics and Screening
• Research Studies
• Reproductive Health
• NIPT (Noninvasive Prenatal Testing)
• PGT (Preimplantation Genetic Testing)
• Newborn Genetic Screening
• Single Gene Analysis
• Genetic and Rare Diseases
• Consumer Genomics
• Agrigenomics & Forensics
• Others
• End-use
• Hospitals and Clinics
• Academic and Research Institutes
• Pharmaceutical and Biotech Companies
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Denmark
• Norway
• Sweden
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Thailand
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of Latin America
• MEA
• GCC
• South Africa
• Turkey
• Rest of MEA

The report also includes profiles for some of the leading companies in the Next Generation Sequencing Market, 2024 to 2034, with a focus on this segment of these companies' operations.

• Leading companies and the potential for market growth
• Illumina, Inc.
• F. Hoffman-La Roche Ltd.
• QIAGEN
• Thermo Fisher Scientific, Inc.
• Bio-Rad Laboratories, Inc.
• PerkinElmer, Inc.
• Eurofins Scientific
• Agilent Technologies
• Tecan Group
• Takara Bio
• 10x Genomics
• GenScript
• Integrated DNA Technologies
• Oxford Nanopore Technologies

Overall world revenue for Next Generation Sequencing Market, 2024 to 2034 in terms of value the market will surpass US$8.0 billion in 2024, our work calculates. We predict strong revenue growth through to 2034.Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

• How will the Next Generation Sequencing Market, 2024 to 2034 report help you?
• In summary, our 300+ page report provides you with the following knowledge:
• Revenue forecasts to 2034 for Next Generation Sequencing Market 2024 to 2034, with forecasts for type, workflow, application, and end-use, each forecast at a global and regional level - discover the industrys' prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2034 for five regional and 20 key national markets - See forecasts for the Next Generation Sequencing Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Argentina, Colombia, Germany, France, UK, Italy, Spain, Denmark, Norway, Sweden, China, India, Japan, Singapore, South Korea, Thailand, GCC Countries, South Africa, Turkey, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market - including company profiles for 14 of the major companies involved in the Next Generation Sequencing Market, 2024 to 2034.
• Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
• Information found nowhere else
• With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Next Generation Sequencing Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Next Generation Sequencing Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report
• 1.6 Who is This Report for?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
• 3.3 Impact Analysis
  • 3.3.1 Market Driving Factors
    • 3.3.1.1 Rapid Technological Advancements is Boosting the NGS Market to Grow
    • 3.3.1.2 Research and Clinical Collaborations is Likely to Augment the NGS market
    • 3.3.1.3 Increasing Healthcare Spending
    • 3.3.1.4 Growing Disease Variation and Prevalence is Contributing to the Growing NGS Technology Demand
  • 3.3.2 Market Restraining Factors
    • 3.3.2.1 Lack of Skilled Professionals is Hampering the Market Growth
    • 3.3.2.2 Pricing Pressure Becomes one of the Main Obstacles to the Expansion of the Global Next Generation Sequencing
    • 3.3.2.3 Privacy and Ethical Challenges
  • 3.3.3 Market Opportunities
    • 3.3.3.1 Personalised Medicine and Precision Oncology Creates a Huge Opportunity for the Market to Grow
    • 3.3.3.2 Adoption of NGS in Biomarker Discovery and Drug Development as NGS have Accelerated the Development of Targeted Therapies
• 3.4 Supply Chain Analysis
• 3.5 Regulatory Framework
• 3.6 Emerging Markets and Megatrends
• 3.7 Porter's Five Forces Analysis
  • 3.7.1 Bargaining Power of Suppliers
  • 3.7.2 Bargaining Power of Buyers
  • 3.7.3 Competitive Rivalry
  • 3.7.4 Threat of Substitutes
  • 3.7.5 Threat of New Entrants
• 3.8 PESTLE Analysis

4 Next Generation Sequencing Market Analysis by Type

• 4.1 Key Findings
• 4.2 Type Segment: Market Attractiveness Index
  • 4.2.1 Next Generation Sequencing Market Size Estimation and Forecast by Type
• 4.3 Consumables
  • 4.3.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.3.2 Market Share by Region, 2024 & 2034 (%)
• 4.4 Bioinformatics
  • 4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.4.2 Market Share by Region, 2024 & 2034 (%)
• 4.5 Sequencing Services
  • 4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.5.2 Market Share by Region, 2024 & 2034 (%)
• 4.6 Pre-Sequencing Services
  • 4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.6.2 Market Share by Region, 2024 & 2034 (%)
• 4.7 Instruments
  • 4.7.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.7.2 Market Share by Region, 2024 & 2034 (%)

5 Next Generation Sequencing Market Analysis by Workflow

• 5.1 Key Findings
• 5.2 Workflow Segment: Market Attractiveness Index
  • 5.2.1 Next Generation Sequencing Market Size Estimation and Forecast by Workflow
• 5.3 Library preparation
  • 5.3.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.3.2 Market Share by Region, 2024 & 2034 (%)
• 5.4 Sequencing
  • 5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.4.2 Market Share by Region, 2024 & 2034 (%)
• 5.5 Data Analysis
  • 5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.5.2 Market Share by Region, 2024 & 2034 (%)

6 Next Generation Sequencing Market Analysis by Application

• 6.1 Key Findings
• 6.2 Application Segment: Market Attractiveness Index
  • 6.2.1 Next Generation Sequencing Market Size Estimation and Forecast by Application
• 6.3 Oncology
  • 6.3.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.3.2 Market Share by Region, 2024 & 2034 (%)
• 6.4 Reproductive Health
  • 6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.4.2 Market Share by Region, 2024 & 2034 (%)
• 6.5 Genetic and Rare Diseases
  • 6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.5.2 Market Share by Region, 2024 & 2034 (%)
• 6.6 Consumer Genomics
  • 6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.6.2 Market Share by Region, 2024 & 2034 (%)
• 6.7 Agrigenomics & Forensics
  • 6.7.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.7.2 Market Share by Region, 2024 & 2034 (%)
• 6.8 Others
  • 6.8.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.8.2 Market Share by Region, 2024 & 2034 (%)

7 Next Generation Sequencing Market Analysis by End-use

• 7.1 Key Findings
• 7.2 End-use Segment: Market Attractiveness Index
  • 7.2.1 Next Generation Sequencing Market Size Estimation and Forecast by End-use
• 7.3 Hospitals and Clinics
  • 7.3.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 7.3.2 Market Share by Region, 2024 & 2034 (%)
• 7.4 Academic and Research Institutes
  • 7.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 7.4.2 Market Share by Region, 2024 & 2034 (%)
• 7.5 Pharmaceutical and Biotech Companies
  • 7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 7.5.2 Market Share by Region, 2024 & 2034 (%)
• 7.6 Others
  • 7.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 7.6.2 Market Share by Region, 2024 & 2034 (%)

8 Next Generation Sequencing Market Analysis by Region

• 8.1 Key Findings
• 8.2 Regional Market Size Estimation and Forecast

9 North America Next Generation Sequencing Market Analysis

• 9.1 Key Findings
• 9.2 North America Next Generation Sequencing Market Attractiveness Index
• 9.3 North America Next Generation Sequencing Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 9.4 North America Next Generation Sequencing Market Size Estimation and Forecast by Country
• 9.5 North America Next Generation Sequencing Market Size Estimation and Forecast by Type
• 9.6 North America Next Generation Sequencing Market Size Estimation and Forecast by Workflow
• 9.7 North America Next Generation Sequencing Market Size Estimation and Forecast by Application
• 9.8 North America Next Generation Sequencing Market Size Estimation and Forecast by End-use
• 9.9 U.S. Next Generation Sequencing Market Analysis
• 9.10 Canada Next Generation Sequencing Market Analysis

10 Europe Next Generation Sequencing Market Analysis

• 10.1 Key Findings
• 10.2 Europe Next Generation Sequencing Market Attractiveness Index
• 10.3 Europe Next Generation Sequencing Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 10.4 Europe Next Generation Sequencing Market Size Estimation and Forecast by Country
• 10.5 Europe Next Generation Sequencing Market Size Estimation and Forecast by Type
• 10.6 Europe Next Generation Sequencing Market Size Estimation and Forecast by Workflow
• 10.7 Europe Next Generation Sequencing Market Size Estimation and Forecast by Application
• 10.8 Europe Next Generation Sequencing Market Size Estimation and Forecast by End-use
• 10.9 Germany Next Generation Sequencing Market Analysis
• 10.10 France Next Generation Sequencing Market Analysis
• 10.11 UK Next Generation Sequencing Market Analysis
• 10.12 Italy Next Generation Sequencing Market Analysis
• 10.13 Spain Next Generation Sequencing Market Analysis
• 10.14 Russia Next Generation Sequencing Market Analysis
• 10.15 Denmark Next Generation Sequencing Market Analysis
• 10.16 Sweden Next Generation Sequencing Market Analysis
• 10.17 Norway Next Generation Sequencing Market Analysis
• 10.18 Rest of Europe Next Generation Sequencing Market Analysis

11 Asia Pacific Next Generation Sequencing Market Analysis

• 11.1 Key Findings
• 11.2 Asia Pacific Next Generation Sequencing Market Attractiveness Index
• 11.3 Asia Pacific Next Generation Sequencing Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 11.4 Asia Pacific Next Generation Sequencing Market Size Estimation and Forecast by Country
• 11.5 Asia Pacific Next Generation Sequencing Market Size Estimation and Forecast by Type
• 11.6 Asia Pacific Next Generation Sequencing Market Size Estimation and Forecast by Workflow
• 11.7 Asia Pacific Next Generation Sequencing Market Size Estimation and Forecast by Application
• 11.8 Asia Pacific Next Generation Sequencing Market Size Estimation and Forecast by End-use
• 11.9 Japan Next Generation Sequencing Market Analysis
• 11.10 China Next Generation Sequencing Market Analysis
• 11.11 India Next Generation Sequencing Market Analysis
• 11.12 Australia Next Generation Sequencing Market Analysis
• 11.13 South Korea Next Generation Sequencing Market Analysis
• 11.14 Singapore Next Generation Sequencing Market Analysis
• 11.15 Thailand Next Generation Sequencing Market Analysis
• 11.16 Rest of Asia Pacific Next Generation Sequencing Market Analysis

12 Latin America Next Generation Sequencing Market Analysis

• 12.1 Key Findings
• 12.2 Latin America Next Generation Sequencing Market Attractiveness Index
• 12.3 Latin America Next Generation Sequencing Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 12.4 Latin America Next Generation Sequencing Market Size Estimation and Forecast by Country
• 12.5 Latin America Next Generation Sequencing Market Size Estimation and Forecast by Type
• 12.6 Latin America Next Generation Sequencing Market Size Estimation and Forecast by Workflow
• 12.7 Latin America Next Generation Sequencing Market Size Estimation and Forecast by Application
• 12.8 Latin America Next Generation Sequencing Market Size Estimation and Forecast by End-use
• 12.9 Brazil Next Generation Sequencing Market Analysis
• 12.10 Mexico Next Generation Sequencing Market Analysis
• 12.11 Argentina Next Generation Sequencing Market Analysis
• 12.12 Colombia Next Generation Sequencing Market Analysis
• 12.13 Rest of Latin America Next Generation Sequencing Market Analysis

13 MEA Next Generation Sequencing Market Analysis

• 13.1 Key Findings
• 13.2 MEA Next Generation Sequencing Market Attractiveness Index
• 13.3 MEA Next Generation Sequencing Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 13.4 MEA Next Generation Sequencing Market Size Estimation and Forecast by Country
• 13.5 MEA Next Generation Sequencing Market Size Estimation and Forecast by Type
• 13.6 MEA Next Generation Sequencing Market Size Estimation and Forecast by Workflow
• 13.7 MEA Next Generation Sequencing Market Size Estimation and Forecast by Application
• 13.8 MEA Next Generation Sequencing Market Size Estimation and Forecast by End-use
• 13.9 GCC Countries Next Generation Sequencing Market Analysis
• 13.10 South Africa Next Generation Sequencing Market Analysis
• 13.11 Turkey Next Generation Sequencing Market Analysis
• 13.12 Rest of MEA Next Generation Sequencing Market Analysis

14 Company Profiles

• 14.1 Competitive Landscape, 2023
• 14.2 Strategic Outlook
• 14.3 Illumina, Inc.
  • 14.3.1 Company Snapshot
  • 14.3.2 Company Overview
  • 14.3.3 Financial Analysis
    • 14.3.3.1 Net Revenue, 2019-2023
    • 14.3.3.2 R&D, 2019-2023
    • 14.3.3.3 Business Segment Market Shares, 2023
    • 14.3.3.4 Regional Market Shares, 2023
  • 14.3.4 Product Benchmarking
  • 14.3.5 Strategic Outlook
  • 14.3.6 SWOT Analysis
• 14.4 F. Hoffmann-La Roche Ltd.
  • 14.4.1 Company Snapshot
  • 14.4.2 Company Overview
  • 14.4.3 Financial Analysis
    • 14.4.3.1 Net Revenue, 2019-2023
    • 14.4.3.2 R&D, 2019-2023
    • 14.4.3.3 Business Segment Market Shares, 2023
  • 14.4.4 Product Benchmarking
  • 14.4.5 Strategic Outlook
  • 14.4.6 SWOT Analysis
• 14.5 QIAGEN
  • 14.5.1 Company Snapshot
  • 14.5.2 Company Overview
  • 14.5.3 Financial Analysis
    • 14.5.3.1 Net Revenue, 2019-2023
    • 14.5.3.2 Business Segment Market Shares, 2023
    • 14.5.3.3 Regional Market Shares, 2023
  • 14.5.4 Product Benchmarking
  • 14.5.5 Strategic Outlook
  • 14.5.6 SWOT Analysis
• 14.6 Thermo Fisher Scientific Inc.
  • 14.6.1 Company Snapshot
  • 14.6.2 Company Overview
  • 14.6.3 Financial Analysis
    • 14.6.3.1 Net Revenue, 2019-2023
    • 14.6.3.2 Business Segment Market Shares, 2023
    • 14.6.3.3 Regional Market Shares, 2023
  • 14.6.4 Product Benchmarking
  • 14.6.5 Strategic Outlook
  • 14.6.6 SWOT Analysis
• 14.7 Bio-Rad Laboratories, Inc.
  • 14.7.1 Company Snapshot
  • 14.7.2 Company Overview
  • 14.7.3 Financial Analysis
    • 14.7.3.1 Net Revenue, 2019-2023
    • 14.7.3.2 Regional Market Shares, 2023
    • 14.7.3.3 Business Segment Market Shares, 2023
  • 14.7.4 Product Benchmarking
  • 14.7.5 Strategic Outlook
  • 14.7.6 SWOT Analysis
• 14.8 PerkinElmer Inc.
  • 14.8.1 Company Snapshot
  • 14.8.2 Company Overview
  • 14.8.3 Product Benchmarking
  • 14.8.4 Strategic Outlook
  • 14.8.5 SWOT Analysis
• 14.9 Eurofins Scientific
  • 14.9.1 Company Snapshot
  • 14.9.2 Company Overview
  • 14.9.3 Financial Analysis
    • 14.9.3.1 Net Revenue, 2019-2023
    • 14.9.3.2 Regional Market Shares, 2023
    • 14.9.3.3 Business Segment Market Shares, 2023
  • 14.9.4 Product Benchmarking
  • 14.9.5 Strategic Outlook
  • 14.9.6 SWOT Analysis
• 14.10 Tecan Group
  • 14.10.1 Company Snapshot
  • 14.10.2 Company Overview
  • 14.10.3 Financial Analysis
    • 14.10.3.1 Net Revenue, 2019-2023
    • 14.10.3.2 Regional Market Shares, 2023
    • 14.10.3.3 Business Segment Market Shares, 2023
  • 14.10.4 Product Benchmarking
  • 14.10.5 Strategic Outlook
• 14.11 Takara Bio
  • 14.11.1 Company Snapshot
  • 14.11.2 Company Overview
  • 14.11.3 Financial Analysis
    • 14.11.3.1 Net Revenue, 2019-2023
    • 14.11.3.2 R&D, 2019-2023
    • 14.11.3.3 Regional Market Shares, 2023
    • 14.11.3.4 Business Segment Market Shares, 2023
  • 14.11.4 Product Benchmarking
  • 14.11.5 Strategic Outlook
• 14.12 10x Genomics
  • 14.12.1 Company Snapshot
  • 14.12.2 Company Overview
  • 14.12.3 Financial Analysis
    • 14.12.3.1 Net Revenue, 2019-2023
    • 14.12.3.2 Business Segment Market Shares, 2023
    • 14.12.3.3 Region Market Shares, 2023
  • 14.12.4 Product Benchmarking
  • 14.12.5 Strategic Outlook
• 14.13 GenScript
  • 14.13.1 Company Snapshot
  • 14.13.2 Company Overview
  • 14.13.3 Financial Analysis
    • 14.13.3.1 Net Revenue, 2019-2023
  • 14.13.4 Product Benchmarking
  • 14.13.5 Strategic Outlook
• 14.14 Integrated DNA Technologies
  • 14.14.1 Company Snapshot
  • 14.14.2 Company Overview
  • 14.14.3 Product Benchmarking
  • 14.14.4 Strategic Outlook
• 14.15 Oxford Nanopore Technologies
  • 14.15.1 Company Snapshot
  • 14.15.2 Company Overview
  • 14.15.3 Financial Analysis
    • 14.15.3.1 Net Revenue, 2019-2023
  • 14.15.4 Product Benchmarking
  • 14.15.5 Strategic Outlook

15 Conclusion and Recommendations

• 15.1 Concluding Remarks from Visiongain
• 15.2 Recommendations for Market Players